Characteristics | Total (N = 819) |
---|---|
N (%) | |
Age (in years) | |
<50 | 348 (42.5) |
≥50 | 471 (57.5) |
NPI score | |
Median (range) | 5.52 (3.0–9.0) |
Treatment group | |
E-CMF | 123 (15.0) |
E-T-CMF | 392 (47.9) |
ET-CMF | 304 (37.1) |
Menopausal status | |
Premenopausal | 375 (45.8) |
Postmenopausal | 444 (54.2) |
Breast surgery | |
Modified radical mastectomy | 579 (70.7) |
Breast-conserving surgery | 240 (29.3) |
ER/PgR status | |
Negative | 165 (21.7) |
Positive | 596 (78.3) |
Histological grade | |
I–II | 406 (49.6) |
III–Undifferentiated | 413 (50.4) |
Tumor size (cm) | |
≤2 | 181 (22.8) |
2–5 | 517 (65.2) |
>5 | 95 (12.0) |
Positive lymph nodes | |
1–3 nodes | 331 (40.5) |
≥4 nodes | 487 (59.5) |
Adjuvant radiation therapy | |
No | 184 (23.2) |
Yes | 609 (76.8) |
Adjuvant hormonal therapy | |
No | 154 (18.9) |
Yes | 661 (81.1) |
Bone metastases | |
No | 711 (88.4) |
Yes | 93 (11.6) |
HER2 status | |
Negative | 593 (76.5) |
Positive | 182 (23.5) |
Ki67 protein expression | |
Low (<20%) | 367 (44.8) |
High (≥20%) | 452 (55.2) |
Subtypes | |
Luminal A | 245 (32.3) |
Luminal B | 248 (32.8) |
Luminal-HER2 | 99 (13.1) |
HER2-enriched | 79 (10.4) |
Triple-negative | 86 (11.4) |
OPN mRNA expression | |
Low (<50th percentile) | 407 (50.0) |
High (≥50th percentile) | 407 (50.0) |
OPN protein expression | |
Low (0–4 Allred score) | 59 (10.8) |
High (5–8 Allred score) | 487 (89.2) |